Early Gilenya Treatment Lessens Disability Progression and Disease Activity in Young RRMS Patients, Study Shows
Early and continuous treatment with Gilenya (fingolimod) in youngĀ people ā those ages 30 years or younger ā with relapsing-remitting multiple sclerosis (RRMS) decreases the risk of disability progression, and lowers annual relapse rates and brain lesions, new analysis from the FREEDOMS and FREEDOMS II trials show. The…